Recently, a team led by Professors Wu Depei, Chen Suning and Xu Yang from the National Clinical Research Center for Hematologic Diseases and the First Affiliated Hospital of Soochow University published the results of a Phase III multicenter randomized controlled trial in the Journal of Clinical Oncology (JCO), a top international oncology journal (Impact Factor = 44.7).

The study demonstrates that adding oral sitagliptin to the conventional graft-versus-host disease (GVHD) prophylaxis regimen for alternative donor transplantation (haploidentical and unrelated donor transplantation) can significantly reduce the risk of acute GVHD post-transplantation, offering a new, safe and low-cost preventive strategy for high-risk transplant recipients. This is the world’s first large-scale Phase III randomized controlled trial investigating sitagliptin for the prophylaxis of acute GVHD in alternative donor transplantation. The team will carry out further research to precisely identify beneficiary populations and optimize individualized medication strategies.
论文链接Paper Link: